Signal · Technology & Procurement Innovation
AI models need more data about biology, and OpenAI is paying to create it
What the source reported
Source-reportedLast year, the clinical trial policy analyst Ruxandra Teslo posted an idea for super-charging medical AI systems: use data from failed biotech companies. By bidding at their bankruptcy proceedings, she proposed, it might be possible to obtain detailed regulatory filings, manufacturing strategies, and safety data—information usually kept hidden as valuable trade secrets. She called these…
- Publication
- MIT Technology Review - All · Trade Publication
- Published
- 15th September 2026
- Original report
- technologyreview.com
ProcIntel stores what the source published in its feed — a headline, a summary and a link. It does not store or reproduce the full article.
What ProcIntel recorded
ProcIntel-derived- Category
- Technology & Procurement Innovation
- Geography
- Global
- Organisations
- None identified
- Collected
- 15th September 2026 · 13:01
Initial assessment ProcIntel's automatic, provisional read of this individual Signal -- Initial Significance and Initial Confidence, computed deterministically before any Event extraction or human review.
A provisional, automatically computed reading of this individual Signal, before Event extraction or human review. Not a final rating.
Initial Significance Moderate (28.0/100). Strongest contributor: Procurement Impact (21.0/30 points). Limiting factor: Geographic Breadth (0.0/10 points). Initial Confidence Low (20.5/100, data sufficiency: Insufficient). Strongest contributor: Source Authority (20.0/40 points). Limiting factor: Specificity (0.0/20 points).
- Strongest contributor
- Procurement Impact
- Limiting factor
- Geographic Breadth